PURPOSE: Myxoinflammatory fibroblastic sarcoma (MIFS) is a rare soft tissue tumour first identified at the end of the 1990s. This study presents our experience and literature reviews focusing on risk of recurrence. METHODS: Rizzoli Orthopaedic Institute database and literature were searched for patients with MIFS observed from 1997 to 2012. Data were analysed in a new database. RESULTS: Five patients underwent surgery at our institute, and 133 cases were retrieved from the literature. Not all clinicopathological data were available: 76/138 were men (55%), median age was 45 [interquartile range (IQR) 34-56] years, median tumour size was three (IQR two to five) centimetres. Common sites of occurrence were hand (24%), fingers (23%) and foot (20%). Pain was present at diagnosis in 14/82 patients (17%), with a median duration of seven (IQR three to 12) months. Surgery was performed for a suspected benign tumour in 88 patients (74%). Resection was incomplete in 45/71 cases (63%); re-excision was performed in 32/45 (71%). At a median follow-up of 26 months, 26/118 patients (22%) developed recurrent disease; median time to recurrence was 15 months (IQR seven to 26). Actuarial relapse-free survival (RFS) at one, three and five years was 93%, 72% and 67%, respectively. At univariate analysis, only symptom duration of six months or less was significantly associated with a worse RFS (p = 0.046). Metastatic disease to lymph nodes and/or lungs was observed in four patients (3%). CONCLUSIONS: Clinicopathological findings confirm the low-grade nature of MIFS. However, local recurrence occurs, and patients may be affected by aggressive forms with a potential for distant metastases. Follow-up is strongly advised.
PURPOSE: Myxoinflammatory fibroblastic sarcoma (MIFS) is a rare soft tissue tumour first identified at the end of the 1990s. This study presents our experience and literature reviews focusing on risk of recurrence. METHODS: Rizzoli Orthopaedic Institute database and literature were searched for patients with MIFS observed from 1997 to 2012. Data were analysed in a new database. RESULTS: Five patients underwent surgery at our institute, and 133 cases were retrieved from the literature. Not all clinicopathological data were available: 76/138 were men (55%), median age was 45 [interquartile range (IQR) 34-56] years, median tumour size was three (IQR two to five) centimetres. Common sites of occurrence were hand (24%), fingers (23%) and foot (20%). Pain was present at diagnosis in 14/82 patients (17%), with a median duration of seven (IQR three to 12) months. Surgery was performed for a suspected benign tumour in 88 patients (74%). Resection was incomplete in 45/71 cases (63%); re-excision was performed in 32/45 (71%). At a median follow-up of 26 months, 26/118 patients (22%) developed recurrent disease; median time to recurrence was 15 months (IQR seven to 26). Actuarial relapse-free survival (RFS) at one, three and five years was 93%, 72% and 67%, respectively. At univariate analysis, only symptom duration of six months or less was significantly associated with a worse RFS (p = 0.046). Metastatic disease to lymph nodes and/or lungs was observed in four patients (3%). CONCLUSIONS: Clinicopathological findings confirm the low-grade nature of MIFS. However, local recurrence occurs, and patients may be affected by aggressive forms with a potential for distant metastases. Follow-up is strongly advised.
Authors: R Gonzalez-Cámpora; J J Ríos-Martín; A Solórzano-Amoretti; M T Vargas de los Monteros; I Trigo-Sánchez; C Otal-Salaverri; H Galera-Davidson Journal: Cytopathology Date: 2007-05-18 Impact factor: 2.073
Authors: Cristiane M Ida; Kristen A Rolig; Rachael L Hulshizer; Daniel L Van Dyke; Jamie L Randolph; Robert B Jenkins; Antonio G Nascimento; Andre M Oliveira Journal: Cancer Genet Cytogenet Date: 2007-09
Authors: Ajay Tejwani; Wendy Kobayashi; Yen-Lin Evelyn Chen; Andrew E Rosenberg; Sam Yoon; Kevin A Raskin; Daniel I Rosenthal; Gunnlaugur P Nielsen; Francis J Hornicek; Thomas F Delaney Journal: Cancer Date: 2010-08-24 Impact factor: 6.860
Authors: Niveditha Jagadesh; Daniel H Miller; William Schenk; Steven Attia; Courtney E Sherman; Cherise Cortese; Byron C May; Robert C Miller Journal: Clin Case Rep Date: 2017-04-20
Authors: Chiel A J van der Horst; Sabien L M Bongers; Yvonne M H Versleijen-Jonkers; Vincent K Y Ho; Pètra M Braam; Uta E Flucke; Johannes H W de Wilt; Ingrid M E Desar Journal: Cancers (Basel) Date: 2022-02-22 Impact factor: 6.639
Authors: David Suster; Michael Michal; Huiya Huang; Shira Ronen; Stephanie Springborn; Maria Debiec-Rychter; Steven D Billings; John R Goldblum; Brian P Rubin; Michal Michal; Saul Suster; A Craig Mackinnon Journal: Mod Pathol Date: 2020-06-08 Impact factor: 7.842